Jubilant Pharmova Ltd - 530019 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Rajiv ShahDesignation :- Company Secretary and Compliance Officer Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that a share certificate has been reported to be lost by the shareholder as per the attachment. The shareholder has requested for issuance of duplicate share certificate in lieu of the original. We propose to issue Duplicate Share Certificate to the shareholder on receipt of the requisite documents. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We enclose copies of the advertisements published on July 1, 2021, in Financial Express (English) - All Editions and Hindustan (Hindi) - Moradabad Edition with respect to notice of transfer of equity shares of the Company to Investor Education and Protection Fund ('IEPF'). This is for your information and record. Jubilant Pharmova Ltd - 530019 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the Financial Year ended March 31, 2021. Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that a share certificate has been reported to be lost by Mrs. Indira A. Savani claiming to be the legal heir of the shareholder as per the attachment. Mrs. Indira A. Savani has requested for issuance of duplicate share certificate in lieu of the original. We propose to issue Duplicate Share Certificate to the legal heir on receipt of the requisite documents. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be participating in Motilal Oswal Ideation Conference, 2021 on June 25, 2021. We enclose details of the Investor/ Analyst for the same. The schedule may undergo change due to exigencies on the part of Investors/ Analysts/ Company. Jubilant Pharmova Ltd - 530019 - Closure of Trading Window
Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company will be closed for the 'Designated Persons' from Thursday, June 24, 2021 and the same shall remain closed till 48 hours after announcement of the financial results for the quarter ending June 30, 2021 to the Stock Exchanges. Analyst and Investor Day: Jubilant Pharmova
Conference Call with Jubilant Pharmova Management and Analysts on Q4FY21 Performance and Outlook. Watch the full transcript. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Investor Presentation
In continuation of our letter dated June 10, 2021, we enclose presentation to be made at Investor and Analyst Meet on June 18, 2021.
Jubilant Pharmova unit joins hands with Ocugen to manufacture Covaxin for US, Canadian markets
Securing US-based manufacturing capability is a critical step the company prepares to submit its regulatory submissions to the FDA and Health Canada, Gabriel added.